Navigation Links
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
Date:1/5/2009

zing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the potential regulatory approval and the benefits of administering rHuPH20 with GAMMAGARD) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a r
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
3. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
7. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
8. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 Progyny, Inc., the ... LLC, announced that it has secured additional capital from ... Biotech, SR One and Merck Serono Ventures. The funding ... patients the best fertility outcomes by aligning science, technology, ... online marketplace for families seeking fertility solutions and we ...
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... , April 20, 2015  "Everybody is affected ... do to patients is frankly brutal. We,ve got to ... a cancer ward, or witnessed a loved one or ... witnessed firsthand the devastation chemotherapy and other treatments cause ... people want to give up and succumb to the ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... DENVER , Aug. 5 Forensic Laboratories, ... for drug and alcohol abuse, has announced the expansion ... the first lab in the nation to develop an ... saliva, a chemical produced by the body after alcohol ...
... KANSAS CITY, Kansas , Aug. 5 Oncimmune® ... test that aids physicians in risk assessment and the early ... study that demonstrates the clinical validity of the test. The study ... Diagnosis " is now available on line at Annals of ...
... reveal how a new type of experimental antibiotic ... existing treatments [1]. The findings could ultimately help ... bacteria responsible for many hospital and community-acquired infections. ... a team of researchers from GlaxoSmithKline (GSK) captured ...
Cached Biology Technology:Forensic Laboratories Develops First Oral Fluid Test for Ethyl Sulfate Detection 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance 2
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Liver transplant patients with hepatitis C virus (HCV) ... the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination ... virus in vitro. , The results of ... of Liver Transplantation, the official journal of the ...
... infants born with HIV infection may be most effective ... according to a study published in the April 1 ... online. , Uncertainty over when to start antiretroviral treatment ... around balancing the benefits of preventing disease progression and ...
... in which single strands of synthetic DNA are used ... been developed by researchers with the Lawrence Berkeley National ... Berkeley. This technique holds promise for a wide ... of artificial tissues and the design of neural networks. ...
Cached Biology News:Cyclosporine inhibits hepatitis C virus in vitro 2New study shows benefit of early therapy in HIV-infected infants 2Berkeley researchers lay groundwork for cell version of DNA chip 2Berkeley researchers lay groundwork for cell version of DNA chip 3Berkeley researchers lay groundwork for cell version of DNA chip 4
... Glutamate receptors constitute the principal ... Two classes of glutamate receptors ... receptors. Ionotropic glutamate receptors are ... (GluR1-7, NMDA1-3, KAI-2) which comprise ...
Recommended fro Western blotting application...
... 15 (KLF15) KLF15 is a Cys2-His2 ... expressed in the liver, kidneys, heart, and ... Specificity: Polyclonal antibody produced in rabbits immunized ... region of human KLF15 with an internal ...
... was developed in the late 1960s by ... the earliest commercial pioneers of immunoassay in ... in 1987. Sac-Cel rapidly found favour with ... "in house" radioimmunoassays, and became a benchmark ...
Biology Products: